[Table_Title] 策略月报 [Table_ 【策略观点】 Summary] 【5月策略】 市场流动性风险；盈利不及预期风险 [Table_Author] 东方财富证券研究所 | --- | --- | |--------------------------|-------------------------------------| | | | | 相关研究 | | | 《 A | 股二季度有望保持结构性复 | | 苏行情》 | | | 《A | 2024.04.01 股全面估值修复还将继续》 | | | 2024.02.29 | | 《等待更强力政策出台帮助 | A 股 | | 筑底》 | | | | 2024.01.31 | | 《 2024 | 春季行情正在出现更多积 | | 极因素》 | | | | 2023.12.29 | | 《静待经济复苏中的 A | 股走过震 | | 荡期》 | | | | 2023.11.30 | | 《A | 股有望在政策和资金面的双 | | 重支持下延续反弹》 | | | | | 策 略 研 究 / 策 略 月 报/ 证 券 研 究 报 告 云路股份（68819 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [12][13]. Core Insights - The company achieved steady growth in performance, with a revenue of 3.31 billion yuan in 2023, representing a year-on-year increase of 10.31%. The net profit attributable to shareholders was 568.12 million yuan, up 22.09% year-on-year [11][19]. - The company focuses on traditional Chinese medicine, particularly in the treatment of orthopedic and cardiovascular diseases, with a strong product lineup that includes unique offerings and high market share products [11][13]. - The company plans to distribute a cash dividend of 0.80 yuan per share, totaling approximately 451.15 million yuan, which accounts for 79.41% of the net profit [11]. Financial Summary - Revenue projections for 2024 and 2025 are set at 3.75 billion yuan and 4.23 billion yuan, respectively, with a forecasted net profit of 680.79 million yuan and 799.04 million yuan for the same years [19]. - The company’s EBITDA is expected to grow from 685.21 million yuan in 2023 to 1.06 billion yuan by 2026, reflecting a strong operational performance [19]. - Key financial ratios indicate a healthy growth trajectory, with an expected EPS of 1.20 yuan in 2024 and a P/E ratio of 20.12 [19].

Investment Rating - The report maintains a rating of "Add" for the company [4] Core Insights - The company reported a revenue of 30.233 billion yuan in 2023, representing a year-on-year increase of 20.34%, with a net profit attributable to shareholders of 13.246 billion yuan, up 27.79% year-on-year [4][8] - The company's profitability has significantly improved, with a gross margin of 88.30% in 2023, an increase of 1.71 percentage points year-on-year, and a net margin of 43.81%, up 2.55 percentage points year-on-year [4][8] - The company is expected to maintain steady growth, with projected revenues of 36.441 billion yuan, 43.197 billion yuan, and 50.367 billion yuan for 2024, 2025, and 2026 respectively [8] Financial Performance Summary - In Q4 2023, the company achieved a revenue of 8.291 billion yuan, a year-on-year increase of 9.10%, and a net profit of 2.680 billion yuan, up 24.78% year-on-year [4] - For Q1 2024, the company reported a revenue of 9.188 billion yuan, a year-on-year increase of 20.74%, and a net profit of 4.574 billion yuan, up 23.20% year-on-year [4] - The company’s operating cash flow reached 10.648 billion yuan in 2023, reflecting a rapid growth of 28.87% year-on-year [4] Product and Market Performance - The company’s mid-to-high-end liquor segment generated a revenue of 26.841 billion yuan, growing by 21.28% year-on-year, while other liquor categories saw a revenue of 3.236 billion yuan, up 22.87% year-on-year [4] - Domestic revenue was 30.056 billion yuan, an increase of 20.37% year-on-year, while international revenue was 1.772 billion yuan, up 15.74% year-on-year [4] - Traditional sales channels generated 28.657 billion yuan, a year-on-year increase of 22.98%, while emerging channels saw a decline of 2.97% to 1.420 billion yuan [4]

T* [Table_Title] 策略周报 短期市场情绪得到基本面保障，节前 有望交投相对企稳 2024 年 04 月 29 日 [Table_Summary] 【策略观点】 (只) 及規模（亿元） 图表 19:2023 年与 2022 年全国法院新收知识产权民事一审案件数量对比 1.1 市场涨跌概览 -25.00 -20.00 -15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 20.00 计算机(申万) 非银金融(申万)美容护理(申万)电子(申万)通信(申万)医药生物(申万)食品饮料(申万)房地产(申万)传媒(申万)国防军工(申万)社会服务(申万)汽车(申万)商贸零售(申万)农林牧渔(申万)轻工制造(申万)环保(申万)电力设备(申万)交通运输(申万)基础化工(申万)机械设备(申万)综合(申万)建筑材料(申万)建筑装饰(申万)家用电器(申万)公用事业(申万)银行(申万)纺织服饰(申万)有色金属(申万)钢铁(申万)石油石化(申万)煤炭(申万) 5日涨跌幅 10日涨跌幅 20日涨跌幅 年初至今 资料来源：Choice 股票板块，东方财富证券研究所，数据截至 2024 年 4 月 ...

[ 轻Ta 工bl 制e_ 造T 行itl 业e] 动 态点评 行 业 研 特种纸行业回暖，掘金稳增长高分红企 究 挖掘价值 投资成长 / 业 轻 [Table_Rank] 工 制 强于大市 （上调） 造 2024 年 04 月 29 日 / [东Ta方bl财e_富Au证th券or研] 究所 证 证券分析师：高博文 券 [Table_Summary] 研 【事项】 证书编号：S1160521080001 究 证券分析师：陈子怡 报  国务院4月12日印发《关于加强监管防范风险推动资本市场高质量 告 证书编号：S1160522070002 发展的若干意见》。强化上市公司现金分红监管。对多年未分红或分 联系人：刘雪莹 红比例偏低的公司，限制大股东减持、实施风险警示。加大对分红优 电话：021-23586475 质公司的激励力度，多措并举推动提高股息率。增强分红稳定性、持 续性和可预期性，推动一年多次分红、预分红、春节前分红。 [相 T对 a指 bl数 e表 _现 Pi cQuote]  工业生产者购进价格指数（PPIRM）：木材及纸浆类连续九个月同比下 2.55% ...

Q1利润增长强劲，AI业务表现可期 公司于 4 月 26 日发布一季报，2024Q1 公司实现营业收入 3.82 亿元， 同比增长 11.05%；实现归母净利润 7673 万，同比增长 57.92%；实现 扣非归母净利润 7297 亿元，同比增长 57.02%。 [Table_Rank] 买入（维持） | --- | --- | |-------------------------------|--------------------| | | | | [Table_ 基本数据 Basedata ] | | | 总市值（百万元 ) | 10925.83 | | 流通市值（百万元 ) | 6964.45 | | 52 周最高/最低（元） | 47.61/21.53 | | 52 周最高/最低（PE） | 47.38/19.76 | | 52 周最高 /最低（PB） | 6.50/2.88 | | 52 周涨幅（%） | 4.37 | | 52 周换手率（%） | 1553.85 | | [Table_Report] 相关研究 | | | 《核心业务稳健发展， | AI 业务增长可 | | 期》 | | | | ...

[Table_Title] 桂林三金（002275）2023年年报&2024Q1点评 [【投资要点】 Table_Summary] 2022.08.24 [Table_PicQuote] 相对指数表现 公 司 研 究/ 医 药 生 物/ 证 券 研 究 报 告 全年业绩稳定增长，新季度受高基数影 响 [Table_yemei]桂林三金（002275）2023 年年报&2024Q1 点评 | --- | --- | --- | --- | --- | |-----------------------------------|---------|---------|-------------------------|---------| | [Table_FinanceInfo 项目\年度 ] | | | 2023A 2024E 2025E 2026E | | | 营业收入（百万元） | 2171.60 | 2397.88 | 2636.18 | 2888.01 | | 增长率 (%) | 10.81% | 10.42% | 9.94% | 9.55% | | EBITDA （百万元） | 623.73 | 63 ...

2024 年 04 月 29 日 T[ [【投资要点】 Table_Summary] 挖掘价值 投资成长 [Table_Rank] 增持（维持） 电话：021-23586475 | --- | --- | |-----------------------------------------|-----------------------------| | | | | [Table_PicQuote] 相对指数表现 | | | 117.16% 88.68% 60.21% | | | 31.73% 3.26% -25.22% 4/28 6/28 8/28 | 10/28 12/28 2/28 4/28 | | 沃尔核材 | 沪深 300 | | [Table_ 基本数据 Basedata ] | | | 总市值（百万元 ) | 18659.10 | | 流通市值（百万元 ) | 18499.90 | | 52 周最高/最低（元） | 14.81/4.97 | | 52 周最高/最低（ PE） | 26.64/9.89 | | 52 周最高/最低（PB） | 3.80/1.31 | | 52 周涨幅（%） | 11 ...

Investment Rating - The investment rating for the company is "Accumulate" [3][5]. Core Insights - The company's net profit attributable to shareholders showed steady growth, with a net profit of 295 million yuan in Q1 2024, representing an increase of 11.58% year-on-year. However, total revenue decreased by 1.73% year-on-year to 2.049 billion yuan, primarily due to a significant decline in pharmaceutical commercial sales, which dropped by 33.74% [2][5]. - The company is increasing its R&D investment, with R&D expenses reaching 199 million yuan in Q1 2024, up 19.88% year-on-year, accounting for 9.71% of total revenue. The company has a robust pipeline with 98 products under development, including 41 innovative drugs [2][5]. - The company's profitability remains stable, with a gross margin of 67.17% and a net profit margin of 14.30% in Q1 2024, both showing improvements compared to the previous year [2]. Summary by Sections Financial Performance - In Q1 2024, the company achieved a revenue of 2.049 billion yuan, down 1.73% year-on-year, while the net profit attributable to shareholders was 295 million yuan, up 11.58% year-on-year. The pharmaceutical industrial revenue increased by 4.83%, while the traditional Chinese medicine segment generated 1.441 billion yuan, up 3.83% [2][5]. - The company forecasts revenue for 2024-2026 to be 9.416 billion yuan, 10.211 billion yuan, and 11.064 billion yuan, respectively, with net profits projected at 1.314 billion yuan, 1.477 billion yuan, and 1.596 billion yuan [5][6]. R&D and Product Pipeline - The company has a diverse R&D pipeline with 98 products, including 41 innovative drugs. In Q1 2024, the R&D expenses were 199 million yuan, reflecting a year-on-year increase of 19.88% [2][5]. - Several innovative traditional Chinese medicine products are in advanced clinical stages, indicating a strong commitment to expanding its product offerings [2]. Profitability Metrics - The company reported a gross margin of 67.17% and a net profit margin of 14.30% in Q1 2024, both of which improved compared to the previous year. The sales, management, and financial expense ratios were 33.83%, 13.28%, and 0.28%, respectively [2].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Insights - The company achieved a revenue of 6.518 billion yuan in 2023, representing a year-on-year growth of 47.56%, and a net profit attributable to shareholders of 332 million yuan, up 53.61% year-on-year [3][10] - The "Yimai Ecological Platform" has accelerated its development, generating revenue of 786 million yuan, a significant increase of 188.52% year-on-year, and accounting for 12.05% of total revenue in 2023 [1][8] - The company is expanding its product categories and exploring new markets, including furniture and toys, while also targeting emerging platforms like TikTok and Temu [11] Financial Performance - In 2023, the gross margin and net margin were 36.96% and 5.35%, respectively, with slight declines of 0.97 and 0.17 percentage points year-on-year [2] - The company expects revenues of 8.478 billion yuan, 10.228 billion yuan, and 11.909 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 448 million yuan, 551 million yuan, and 648 million yuan [8][9] - The cross-border e-commerce segment generated 5.696 billion yuan in revenue, reflecting a year-on-year growth of 38.62% [10] Strategic Initiatives - The company is focusing on a dual strategy of enhancing its core business while developing premium products and the Yimai Ecological Platform, aiming for sustained growth [8] - The introduction of a "semi-managed" service model on the Yimai platform is expected to help small and medium-sized sellers expand their overseas markets efficiently [11]